Abnormal expression of FOXM1 in carcinogenesis of renal cell carcinoma: From experimental findings to clinical applications
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2023.149251 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Yanmei Shan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, 318000, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: Royal College of Chiropractors, Science and Technology Plan Project of Taizhou.
Abstract (Originalsprache)
Renal cell carcinoma (RCC) is a prevalent malignancy within the genitourinary system. At present, patients with high-grade or advanced RCC continue to have a bleak prognosis. Mounting research have emphasized the significant involvement of Forkhead box M1 (FOXM1) in RCC development and progression. Therefore, it is imperative to consolidate the existing evidence regarding the contributions of FOXM1 to RCC tumorigenesis through a comprehensive review. This study elucidated the essential functions of FOXM1 in promoting RCC growth, invasion, and metastasis by regulating cell cycle progression, DNA repair, angiogenesis, and epithelial-mesenchymal transition (EMT). Also, FOXM1 might serve as a novel diagnostic and prognostic biomarker as well as a therapeutic target for RCC. Clinical findings demonstrated that the expression of FOXM1 was markedly upregulated in RCC samples, while a high level of FOXM1 was found to be associated with a poor overall survival rate of RCC. Furthermore, it is worth noting that FOXM1 may have a significant impact on the resistance of renal cell carcinoma (RCC) to radiotherapy. This observation suggests that inhibiting FOXM1 could be a promising strategy to impede the progression of RCC and enhance its sensitivity to radiotherapy. The present review highlighted the pivotal role of FOXM1 in RCC development. FOXM1 has the capacity to emerge as not only a valuable diagnostic and prognostic tool but also a viable therapeutic option for unresectable RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, 318000, China.
- Postgraduate Department, First Affiliated Hospital of Gannan Medical College, Ganzhou, China.
- Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- Department of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, Jiangxi, China; Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, 341000, Jiangxi, China.
Förderung
- Royal College of Chiropractors
- Science and Technology Plan Project of Taizhou
Zitieren
APA
Shan, Y., Zheng, L., Zhang, S., & Qian, B. (2024). Abnormal expression of FOXM1 in carcinogenesis of renal cell carcinoma: From experimental findings to clinical applications. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.149251
Vancouver
Shan Y, Zheng L, Zhang S, Qian B. Abnormal expression of FOXM1 in carcinogenesis of renal cell carcinoma: From experimental findings to clinical applications. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2023.149251
BibTeX
@article{Shan2024,
author = {Shan, Yanmei and Zheng, Liying and Zhang, Shilong and Qian, Biao},
title = {Abnormal expression of FOXM1 in carcinogenesis of renal cell carcinoma: From experimental findings to clinical applications},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2023.149251}
}
EUVIMED